ASH 2023: Exploring Therapeutic Advancements for Chronic Lymphocytic Leukemia - Episode 11

Role of Non-Covalent BTKis in R/R CLL: Updates from Ongoing BRUIN and Bellwave Trials

February 9, 2024

Catherine C. Coombs, MD, Brian T. Hill, MD, PhD, Ryan W. Jacobs, MD, Jacqueline Barrientos, MD, MS, Javier Pinilla-Ibarz, MD, PhD, Joanna M. Rhodes, MD, MSCE

Jacqueline Barrientos, MD, MS, discusses the role of non-covalent BTK inhibitors in R/R CLL and provided concise comments on the latest data, including insights from the ongoing BRUIN and Bellwave trials.

EP. 1: Current Front-Line Treatment Options for CLL in 2023

EP. 2: Exploring BTKi Monotherapy in CLL: Long-Term Updates from ELEVATE-TN and SEQUOIA

EP. 3: Strategies for Managing Treatment-Naïve CLL with High-Risk Features

EP. 4: Impact of Off-Target AEs and Treatment Resistance on Evolving 1L Therapy Strategies for CLL

EP. 5: Exploring the Role of BTKi-Based Combination Therapies for Front-line Management of CLL

EP. 6: Treatment Sequencing Strategies for R/R CLL: Impact of Prior 1L Therapy

EP. 7: Navigating BTKi Therapy in R/R CLL: Updates from ELEVATE-RR and ALPINE

EP. 8: Expert Perspectives on Navigating Treatment Selection with BTKis in CLL

EP. 9: Expert Insights into Navigating Cardiovascular Risks with BTKi Therapy

EP. 10: Treatment Resistance with Covalent BTKis: Translating Data into Clinical Practice

Now Viewing

EP. 11: Role of Non-Covalent BTKis in R/R CLL: Updates from Ongoing BRUIN and Bellwave Trials

EP. 12: Emerging Data Surrounding Mechanisms of Resistance to Non-Covalent BTKis

EP. 13: Expert Insights into Investigation Therapies for CLL

EP. 14: Future Perspectives on the Treatment Landscape for CLL